Haptoglobin Therapy Prevents Kidney Injury in Stored Blood Resuscitation of Murine Hemorrhagic Shock

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 761-761
Author(s):  
Jan A. Graw ◽  
Ivy A. Rosales ◽  
Yumin Liu ◽  
Venkata S. Sabbisetti ◽  
Frank E. Riley ◽  
...  

Abstract Introduction: Extracellular hemoglobin (Hb) and free heme are major breakdown products of hemolyzing Red Blood Cells (RBC). Mammals have evolved scavenger systems to bind circulating Hb with haptoglobin (Hp) and free heme with hemopexin (Hx). During storage RBC undergo numerous morphological and biochemical changes. Transfusion of stored RBC (SRBC) increases plasma levels of heme and Hb. Increased plasma Hb levels are associated with kidney injury (KI). In prolonged hemorrhagic shock (HS) systemic hypotension and hypoperfusion impair kidney function. KI is an important complication of HS and is associated with a markedly increased mortality and morbidity rate. In this study we employed a murine model of 14-day blood storage mimicking 42-day human blood storage. We first determined that HS-induced KI is more severe in mice resuscitated with SRBC than in those transfused fresh RBC (FRBC). Then we studied whether treatment with either Hp or Hx during transfusion reduced KI after SRBC-resuscitation from HS. Methods: Leukoreduced, packed RBC obtained from WT C57BL6 mice were stored in CPDA-1 at 4°C for either <24 h (FRBC) or 2 weeks (SRBC). Anesthetized mice were bled approximately 50-60% of circulating blood volume over 10 min to maintain a constant mean arterial pressure of 35 mmHg and induce HS. After 120 min of HS, mice were resuscitated with either FRBC or SRBC. Sham operated mice that did not undergo hemorrhagic shock or resuscitation served as a control group. Furthermore, some mice receiving SRBC were given a co-infusion of 7.5 mg of either Hp, or Hx or albumin (Alb) during transfusion. The Alb treated group of mice served as a control for the treatment protein loading. After recovery from anesthesia, urine was collected for 24 h in a metabolic chamber. Urine creatinine, hemoglobin, and Kidney Injury Molecule-1 (KIM-1) were measured. At 48 h post HS the mice were sacrificed and plasma markers of liver and kidney injury were measured. Kidney injury was quantified by a kidney pathology scoring system. Results: After HS and resuscitation hemoglobinuria was detected in 24 h urine samples collected from mice resuscitated with SRBC (see Table). Urine KIM-1 levels were increased after HS and resuscitation with either FRBC or SRBC (FRBC differs vs. Sham, p<0.01; SRBC differs vs. Sham, p<0.05). Plasma NGAL-levels and the kidney tubular injury score were greater in SRBC-transfused mice than in Sham operated mice or FRBC-resuscitated mice (KI score: SRBC differs vs. Sham and FRBC, p<0.01). Hemoglobinuria was present in SRBC-resuscitated mice treated with Alb or Hx but not SRBC transfused mice treated with Hp. Plasma NGAL levels at 48 h after shock did not differ in mice resuscitated with SRBC+Hp or FRBC but were greater in mice resuscitated with SRBC+Alb and SRBC+Hx. Plasma Hb levels at 48 h after resuscitation were less than 33.1±6.4 mg/ml and did not differ from Sham levels between all groups, but plasma Hb levels were 7-fold increased to 231.7±25.7 mg/ml in mice transfused with SRBC+Hp (SRBC+Hp differs vs. all other groups; p<0.001). Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were greater after resuscitation with SRBC and with all three treatments than after resuscitation with FRBC. Conclusion: In comparison to resuscitation from HS with FRBC, resuscitation with SRBC produced hemoglobinuria and greater KI. Treatment with exogenous Hp during transfusion but not treatment with Hx or Alb reduced SRBC-induced hemoglobinuria and prevented kidney injury after HS and resuscitation with SRBC. Treatment with exogenous Hp may prevent KI associated with high plasma Hb concentrations such as after massive transfusion of stored blood, prolonged cardiopulmonary bypass or in acute exacerbations of hemolytic disease. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 791-791
Author(s):  
Binglan Yu ◽  
Liu Han ◽  
Patricio A Leyton ◽  
Kenneth D. Bloch ◽  
Warren M. Zapol

Abstract Introduction Blood transfusion is a lifesaving treatment for hemorrhagic shock. During storage, red blood cells (RBC) undergo progressive deleterious functional, biochemical and structural alterations, which are collectively termed the “storage lesion”. The association between transfusion of blood stored for more than 14 days and adverse clinical outcomes (increased infection, multi-organ failure and mortality) is controversial. Studying mice with hemorrhagic shock, we recently found that resuscitation with blood stored for prolonged periods (SRBC) was associated with worse outcomes than was resuscitation with fresh blood (FRBC). The mechanisms responsible for the adverse effects associated with transfusion of SRBC are incompletely characterized. However, it is known that transfusion of SRBC increases plasma levels of hemoglobin (Hb), which can scavenge vascular nitric oxide (NO). Intravenous infusion of a solution containing cell-free Hb induces systemic hypertension in wild-type (WT) mice, but not in mice that are congenitally deficient in NO synthase 3 (NOS3-/-). In the present study, we sought to determine if NOS3-/- mice are protected from the adverse effects associated with resuscitation of hemorrhagic shock with SRBC. Methods Leukoreduced, packed RBC from WT C57BL6 mice were stored with 14% CPDA-1 anticoagulant at 4°C for either ≤24 h (FRBC) or 2 weeks (SRBC). Mice, of each genotype that were not subjected to hemorrhagic shock or resuscitation, served as control groups. Anesthetized WT mice and NOS3-/- mice (on a C57BL6 background) were bled to a mean arterial pressure (MAP) of 40 mmHg over 10 min. After 90 min of hemorrhagic shock, mice were resuscitated with FRBC or SRBC. Survival rates for up to 7 days were determined. In addition, blood and tissue samples were collected at 4 h after resuscitation to measure plasma markers of liver and kidney injury, plasma Hb and interleukin 6 (IL-6) levels, tissue IL-6 mRNA levels, and pulmonary myeloperoxidase activity and mRNA levels. All data are expressed as mean±SD. Results Baseline MAP under anesthesia was higher in NOS3-/- mice than in WT mice (111±4 vs 83±5 mmHg; P&lt;0.01). After hemorrhagic shock and resuscitation with either FRBC or SRBC, MAP returned to the respective baseline values in each genotype. Survival rates at one week did not differ between WT or NOS3-/- mice resuscitated with either FRBC or SRBC. In both genotypes, after hemorrhagic shock, resuscitation with FRBC elevated plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities similarly as compared to a control group (P&lt;0.01). Plasma levels of ALT and AST were greater after resuscitation with SRBC than after resuscitation with FRBC in both genotypes at 4 h (P&lt;0.01). Resuscitation with SRBC, but not FRBC, increased plasma blood urea nitrogen and creatinine levels similarly in WT and NOS3-/- mice. Plasma Hb levels were greater in mice resuscitated with SRBC than in those resuscitated with FRBC in both genotypes at 4 h after resuscitation (WT: 202±79 vs 5±2 µM, respectively; NOS3-/-: 240±51 vs 14±3 µM, respectively; P&lt;0.001 for both). At 4 h after resuscitation, plasma IL-6 levels were greater in mice treated with SRBC than in mice treated with FRBC in both genotypes (WT: 0.8±0.1 vs 0.5±0.1 ng/ml, respectively; NOS3-/-: 0.8±0.1 vs 0.4±0.1 ng/ml; P&lt;0.01 for both). In both WT and NOS3-/- mice, IL-6 mRNA levels were greater in the liver, kidney, and spleen after resuscitation with SRBC than after resuscitation with FRBC (P&lt;0.01, all values differ SRBC vs FRBC for both genotypes). Pulmonary myeloperoxidase activity and mRNA levels were greater in both genotypes after resuscitation with SRBC than mice resuscitated with FRBC (P&lt;0.01, all values differ SRBC vs FRBC for both genotypes). Conclusions Survival rate after hemorrhagic shock did not differ in WT and NOS3-/- mice resuscitated with either FRBC or SRBC. Resuscitation with SRBC induced greater tissue injury and a more marked inflammatory response than did resuscitation with FRBC, but there was no difference between the genotypes. Our data suggest that mice with NOS3 deficiency are not protected from the adverse effects associated with resuscitation of hemorrhagic shock with SRBC. These findings suggest that the adverse effects of transfusing blood stored for prolonged periods in mice with hemorrhagic shock are not exclusively attributable to scavenging of NOS3-generated NO by increased plasma Hb levels. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4284-4284
Author(s):  
J. Valentin Garcia. Gutierrez ◽  
Jesús Odriozola ◽  
Pilar Herrera ◽  
Javier Lopez ◽  
Maria Calbacho ◽  
...  

Abstract Abstract 4284 Introduction Imatinib (IM), 400 mg/d. induces durable responses in chronic myeloid leukaemia (CML) in chronic phase (CP). However, although IM-biodisponibility is fairly good, its plasma levels are variable and can not be predicted. Recently, these plasma concentrations have been related both to the dose being administrated and to the cytogenetic and molecular responses. Thus, Imatinib pharmacokinetics could be an issue towards treatment optimisation in CML patients. Recent studies suggest that therapeutic IM plasma levels should be above 1040 ng/dl. Aims To evaluate the association between IM dose and throughout plasma levels with different clinical outcomes. Results In this study, we looked for an association between plasma concentrations and clinical outcomes in 16/86 CML chronic phase patients who did not achieve optimal responses following the European Leukemia Net guidelines (ELN) (table 1). Patients with optimal responses and treated with the same standard doses were also analysed as a control group. Patients receiving doses above 400 mg showed throughout plasma levels considered as appropriate. In 7 of 16 patients (47.5%) not achieving optimal responses (ELN criteria), plasma levels were below the supposed therapeutic ranges. We have found no evidence for a correlation between clinical risk factors at diagnosis and the measurement of optimal plasma levels. Conclusions IM plasma levels are well correlated with IM dose administrated in the patients studied. In almost 50% of patients who did not achieve optimal responses, IM plasma levels were under the ranges considered therapeutic. Probably these are the patients who may benefit of a dose increase. Obviously, to learn more about the practical value of these measurements a longer follow up with a larger number of patients is needed. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3987-3987
Author(s):  
Paolo Bucciarelli ◽  
Emanuele Previtali ◽  
Ida Martinelli ◽  
Andrea Artoni ◽  
Serena M Passamonti ◽  
...  

Abstract Abstract 3987 Poster Board III-923 Background Microparticles (MPs) are circulating, submicroscopic fragments (<1 μm of diameter) of membrane-bound cytoplasm that shed from the surface of an activated or apoptotic cell and play a role in coagulation, inflammation, cell remodelling and proliferation. There is increasing evidence that MPs are involved in thrombosis, but whether or not they are an independent risk factor for venous thromboembolism (VTE) is not established. Aim of the study To investigate the association between high plasma levels of MPs and risk of VTE Patients and Methods In a case-control study, 186 patients with a first episode of VTE (deep venous thrombosis and/or pulmonary embolism) and 418 healthy controls were included. MPs were analyzed by flow cytometry with a gate defined by a 1 μm beads and using APC-Annexin V together with FITC anti-CD41 or FITC anti-CD142 antibodies in order to identify platelet MPs (MP-Plts) and MPs exposing tissue factor (MP-TF), respectively. MPs levels were expressed as number/μL. Results Patients had significantly higher median plasma levels of both MPs-Plts and MPs-TF than controls [1942 vs 1519 (p<0.0001) and 579 vs 454 (p<0.0001)]. Higher median levels of MP-Plts and MP-TF were found in 41 patients who underwent blood sampling within 6 months from VTE than in those sampled later [2114 vs 1694 (p=0.086) and 652 vs 543 (p=0.120)]. Sex, age, body mass index and factor VIII plasma levels had no influence on MPs levels, as well as the use of oral contraceptives (this latter evaluated only in controls). In the whole study population, carriership of thrombophilia (antithrombin, protein C or protein S deficiency, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies, hyperhomocysteinemia or combined abnormalities) had higher levels of MP-Plts and MP-TF than non-carriers [1907 vs 1565 (p=0.002) and 532 vs 468 (p=0.011)]. The odds ratio (OR) for VTE, adjusted for sex, age, body mass index and thrombophilia was 2.5-fold higher in individuals with MPs plasma levels >95th percentile of the control group (3633/μL for MPs-Plts and 1113/μL for MPs-TF) than in those with MPs levels ≤95th percentile [for MPs-Plts: OR=2.59 (95%CI 1.23 – 5.45); for MPs-TF: OR=2.38 (1.15 – 4.92)]. The risk increased in a dose-dependent manner for both MPs-Plts and MPs-TF, particularly above the 75th percentile of the distribution in controls. The exclusion of patients whose MPs levels were measured within 6 months from VTE (in order to avoid the possible effect of the acute phase on MPs measurements), did not change the results [adjusted OR: 2.63 (1.18 – 5.89) for MPs-Plts and 2.36 (1.10 – 5.19) for MPs-TF]. The Table shows the relative risks of VTE associated with the presence or absence of high MPs levels and thrombophilia. Individuals with MPs >95th percentile or thrombophilia alone had a 2 to 3-fold increased risk of VTE, whereas those with both MPs-Plts >95th percentile and thrombophilia had a 9-fold increased risk of VTE. This synergistic effect was confirmed also for MPs-TF and remained after the exclusion of patients whose blood sample was collected within 6 months from VTE [OR 7.72 (1.68-35.4) for MP-Plts and 8.14 (2.08-31.8) for MP-TF]. Conclusions Plasma levels of MPs are significantly higher in patients with VTE than in healthy controls. MPs levels >95th percentile are associated with a 2.5-fold increased risk of VTE. There is a synergistic interaction between high levels of MPs and thrombophilia on VTE risk. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3348-3348
Author(s):  
Luis Fernando Bittar ◽  
Bruna Mazetto Fonseca ◽  
Silmara Lima Montalvão ◽  
Fernanda Loureiro de Andrade Orsi ◽  
Erich V de Paula ◽  
...  

Abstract Abstract 3348 Introduction: Venous thromboembolism (VTE) is a multifactorial disease, and increased levels of coagulation factor VIII (FVIII) has been demonstrated as risk factor for first and recurrent episodes of VTE. Some authors reported that these high levels of FVIII were still persistent after 4 years of the episode, but median follow-up in these studies are relatively short. The aim of the study was investigate if after a long-term follow-up of 4–15 years (median of 10 years), patients with high levels of FVIII after anticoagulant treatment still showed this alteration. Design and Methods: Previously, we selected 174 adult patients with a first episode of acute VTE between January 1990 and September 2004. One hundred seventy four healthy adult individuals selected from blood donors were chosen as controls, from the same geographic area of origin. Of this group of VTE patients, 68 patients with plasma FVIII: C levels above the 90th percentile were selected. FVIII levels (FVIII:C) were measured by a one-stage clotting assay with FVIII-deficient plasma in duplicate in an automated coagulometer. Levels were measured twice, in 2004 and then in 2011. C-reactive protein (CRP) levels were determined in the same samples by a nephelometric method to evaluate the influence of inflammation on FVIII levels. For individuals with CRP values higher than 1mg/dL, an additional blood sample was analyzed. High FVIII levels were only considered for further analysis when in the presence of normal CRP levels. The presence of post-thrombotic syndrome (PTS) was evaluated and classified clinically by the Clinical-Etiologic-Anatomic-Pathophysiologic (CEAP) classification System. Results: 68 patients with VTE and high levels of FVIII (19M:49F) with a median age of 47 years (range 20–70) were included in the study. The control group consisted of 59 subjects (42M:17F) with a median age of 35 years (range 21–56 years). VTE was spontaneous in 26 (38.2%) patients and secondary to an acquired risk factor in 61.8%. In the 1st evaluation, in 2004, patients with VTE had higher plasma levels of FVIII:C (median 235.8 IU/dL vs. 127.0 IU/dL; p<0.001) compared to controls. In 2011, seven years after the first evaluation and after a median follow-up of 10 years after the first VTE episode, this difference was still present (median 144.6 IU/dL vs. 96.4 IU/dL; p<0.001). Patients with severe PTS (167 IU/dL) showed higher plasma levels of FVIII when compared with patients without PTS (median 141.4 IU/dL), mild PTS patients (median 142.8 IU/dL), and moderate PTS patients (median 143.2); p=0.04. Conclusions: Our results show that even after a median of 10 years of VTE, patients still have increased levels of FVIII. Moreover, there seems to be a relationship between severe post-thrombotic syndrome and increased plasma levels of FVIII. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 162-162 ◽  
Author(s):  
Erica M Sparkenbaugh ◽  
Camille Faes ◽  
Denis Noubouossie ◽  
Daniel K. Kirchhofer ◽  
András Gruber ◽  
...  

Abstract Sickle cell disease (SCD) is associated with chronic activation of coagulation. Previously, we demonstrated that inhibition of tissue factor (TF) attenuates thrombin generation (measured by plasma levels of thrombin-antithrombin complexes [TAT]) in a mouse model of SCD during steady state. Furthermore, we showed that neither inhibition of FXIIa-dependent activation of FXI (using 14E11 antibody) nor FXI deficiency reduces thrombin generation (TG) in sickle mice. In contrast, genetic deficiency of FXII or kininogen (HK) reduced plasma TAT levels. These data suggest that during steady state, FXIIa contributes to TG in sickle mice via activation of the kallikrein/HK pathway, but not FXI. In the present study, we further investigated the mechanisms of HK-induced TG at steady state, and increased TG observed during vaso-occlusive crisis (VOC). All experiments were performed using 4-5 month old Townes SS (sickle) and AA (control) mice. Kallikrein cleaves HK into HK fragments (HKFs) and bradykinin (BK). First, we investigated whether a BK-mediated increase in vascular permeability contributes to TG by exposing perivascular TF. This hypothesis was disproved by data demonstrating no difference in vascular permeability (measured by the extravasation of Evans blue in the heart, lung, liver and kidney) between AA (n=8) and SS (n=10) mice. HKFs were shown to induce leukocyte TF expression in vitro via binding to CD11b/CD18 (Mac-1). Therefore, we investigated whether Mac-1 inhibition affects TG in SS mice. AA and SS mice were treated with an inhibitory anti Mac-1 (M1/70) or IgG control antibody on days 0, 3 and 6 (i.p. 1 mg/kg) and TG was analyzed 1 day after the last injection. In the control group, SS mice demonstrated higher plasma TAT levels compared to AA mice (8.1±1.6 vs 4.2±0.6 ng/mL, n=10-11, p<0.05), but inhibition of Mac-1 significantly reduced plasma TAT levels in SS mice (4.6±0.7 ng/mL, n=11, p<0.05). These data suggest that HK might contribute to TG during steady state via Mac-1-dependent induction of monocyte TF. The steady state of SCD is interspersed with acute periods of VOC. Clinical data demonstrate that compared to the steady state, plasma levels of cell free DNA (cfDNA), activation of the contact system, and TG are further enhanced during VOC. To determine the mechanism of increased TG during VOC, we used the previously characterized mouse model of TNFα -induced VOC. Townes AA and SS mice were injected with recombinant TNFα (2 µg/g body weight) or the same volume of PBS, and plasma was collected 5 hours later. TNFα not only dramatically increased plasma levels of cfDNA in SS mice (14.78 ± 1.64 vs 679 ± 300 ng/mL; p<0.01), but also further increased plasma TAT levels compared to those observed in PBS-treated SS mice (2.9 fold, p<0.001, n=8). Importantly, there was a significant positive correlation between cfDNA and TAT in SS mice (r2 =0.65, p<0.001). Since cfDNA can activate FXII, we determined whether FXIIa-dependent activation of FXI contributes to TG during VOC. AA and SS mice received 14E11 or IgG control (4 mg/kg) 30 minutes before TNFα (2 μg/g) or PBS injection, and plasma TAT was assessed 5 hours later. Strikingly, 14E11 attenuated the increased TAT level in TNFα-treated SS mice, to the level observed in SS mice injected with PBS and IgG (IgG/SS/PBS: 9 ng/mL ± 1.8 vs. IgG/SS/TNF: 18.9 ± 3.6, p<0.001; 14E11/SS/TNF: 9.86 ± 0.72, p<0.05 vs. IgG/SS/TNF). We also determined if TF activity is required for the increased TG observed during VOC. Interestingly, inhibition of TF with an inhibitory 1H1 antibody (25 or 75 mg/kg injected i.p. 1 or 18 hours prior to TNFα, respectively) had no effect on the increased TG observed in TNFα treated SS mice. In aggregate, our data suggest that during the steady state of SCD, FXII-dependent TG is not FXI-dependent, but instead is mediated by a pathway involving HK, Mac-1 integrin and leukocyte TF. Furthermore, we propose that during VOC the massive release of cfDNA results in FXIIa-dependent FXI activation and enhances TG independently of TF. This study provides mechanistic insight into the initiators of TG in SCD. Moreover, it implicates FXIIa as a potential therapeutic target to reduce the prothrombotic state in SCD, during both steady state and VOC. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Isabella Viana Gomes Schettini ◽  
Débora Vargas Faria ◽  
Leilismara Sousa Nogueira ◽  
Alba Otoni ◽  
Ana Cristina Simões e Silva ◽  
...  

Abstract Introduction: Studies have shown that the renin angiotensin aldosterone system (RAAS) and inflammation are related to kidney injury progression. The aim of this study was to evaluate RAAS molecules and chemokine (C-C motif) ligand 2 (CCL2) in 82 patients with chronic kidney disease (CKD). Methods: Patients were divided into two groups: patients diagnosed with CKD and patients without a CKD diagnosis. Glomerular filtration rate (GFR) and albumin/creatinine ratio (ACR) were determined, as well as plasma levels of angiotensin-(1-7) [Ang-(1-7)], angiotensin-converting enzyme (ACE)1, ACE2, and plasma and urinary levels of CCL2. Results: CCL2 plasma levels were significantly higher in patients with CKD compared to the control group. Patients with lower GFR had higher plasma levels of ACE2 and CCL2 and lower ratio ACE1/ACE2. Patients with higher ACR values had higher ACE1 plasma levels. Conclusion: Patients with CKD showed greater activity of both RAAS axes, the classic and alternative, and higher plasma levels of CCL2. Therefore, plasma levels of RAAS molecules and CCL2 seem to be promising prognostic markers and even therapeutic targets for CKD.


2014 ◽  
Vol 34 (2) ◽  
pp. 127-134 ◽  
Author(s):  
E Altinoz ◽  
Z Oner ◽  
H Elbe ◽  
Y Cigremis ◽  
Y Turkoz

The reactive oxygen species take role in pathogenesis of many diseases including hypoxia, hypercholesterolemia, atherosclerosis, nephropathy, hypertension, ischemia–reperfusion damage, and heart defects. The aim of this study was to evaluate whether crocin administration could protect kidney injury from oxidative stress in streptozotocin-induced diabetic rats. The rats were randomly divided into 3 groups each containing 10 animals as follows: group 1, control group; group 2, diabetes mellitus (DM) group; and group 3, DM + crocin group. At the end of the study, trunk blood was collected to determine the plasma levels of blood urea nitrogen (BUN) and creatinine (Cr). The kidney tissue was removed, and biochemical and histological changes were examined. Diabetes caused a significant increase in malondialdehyde (MDA) and xanthine oxidase (XO) activities and a decrease in glutathione (GSH) contents (  p < 0.01) when compared with control group in the rat kidneys. Crocin given to DM rats significantly decreased MDA (  p < 0.01) and XO (  p < 0.05) activities and elevated GSH (  p < 0.05) contents when compared with DM group. Plasma levels of BUN and Cr were significantly higher in the DM group when compared with the control group (  p < 0.01). Pretreatment of the DM animals with crocin decreased the high level of serum Cr and BUN. Control group was normal in histological appearance, but congestion, severe inflammation, tubular desquamation, tubular necrosis, and hydropic degeneration in tubular cells were observed in the DM group. Histopathological changes markedly reduced, and appearance of kidney was nearly similar to control group in DM + crocin group. Our results show that crocin could be beneficial in reducing diabetes-induced renal injury.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2975-2975
Author(s):  
Marinez F Matos ◽  
Dayse M Lourenço ◽  
Cristina M Orikaza ◽  
Maria A E Noguti ◽  
Vânia M Morelli

Abstract Abstract 2975 Poster Board II-953 Background: high levels of some cytokines have been associated with an increased risk of venous thromboembolism (VTE) in some case-control studies, but not in prospective studies. However, data regarding the impact of cytokines levels on the risk of VTE are still limited. The aim of this study was to investigate the association between the risk of VTE and plasma levels of interleukin (IL)-1β, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-αa and monocyte chemotactic protein (MCP)-1. Materials and Methods: we studied 122 patients (96 women, 79%), with a first objectively confirmed episode of VTE and with a median age of 39.5 years (range: 21-60). Exclusion criteria were malignancy, autoimmune diseases, antiphospholipid syndrome, chronic renal or liver disease and arterial thrombosis. Patients were seen at least 1 month after the discontinuation of the anticoagulant treatment and > 7 months after the event of VTE. Control group was comprised of 131 healthy subjects (105 women, 80%), with median age of 38 years (range: 18-66), recruited via the patients from the same geographic region and ethnic background. Controls were matched for age and sex. Plasma levels of cytokines were measured by commercial ELISA and a highly sensitive assay was used to measure IL-1β, IL-6 and IL-10 levels. Since a high percentage of samples of IL-1β (73%), IL-10 (62%) and TNF-αa (97%) was below the lower limit of detection (LLD) of the assay, levels of these cytokines were categorized as detectable (> LLD) and not detectable (< LLD). Elevated levels of IL-6 (> 2.15pg/mL), IL-8 (> 10.11pg/mL) and MCP-1 (> 84.11pg/mL) were defined by plasma concentration of these cytokines exceeding the 90th percentile of the distribution of the control population. Results: elevated levels of IL-6 were detected in 27% of the patients with VTE in comparison with 10% (by definition) of the controls [odds ratios (OR) = 3.4, 95% Confidence Interval (CI) 1.6 - 7.6]. Elevated levels of IL-8 were detected in 21% of the patients in comparison with 10% of the controls (OR = 2.5, 95%CI 1.1 - 5.6). The risk remained significant for IL-6 (OR = 2.8, 95%CI 1.2 - 6.5) and IL-8 (OR = 2.6, 95%CI 1.1 - 6.7) after adjustment for putative confounders (sex, age, body mass index, smoking and high levels of homocysteine and C-reactive protein). On the other hand, we found no significant association between VTE and elevated levels of MCP-1 (OR = 0.8, 95%CI 0.3 - 1.9) as well as detectable levels of IL-1β (OR = 0.9, 95%CI 0.5-1.6), IL-10 (OR = 1.3, 95%CI 0.8 - 2.2) and TNF-αa (OR = 6.7, 95%CI 0.8 - 56.7). In our study, patients were included at different time intervals after the VTE episode [median: 36 months (range: 7-87)]. No correlation was found between the time since the event of VTE and levels of IL-6 (rs = 0.06, P = 0.54) and IL-8 (rs= 0.07; P = 0.48). Conclusion: this study shows a significant impact of elevated levels of IL-6 and IL-8 on the risk of VTE in a relatively young population of patients. Interestingly, no association was found between the time since the event and the level of these cytokines. Taking into account the importance of the relationship between inflammation and VTE, more epidemiological data including prospective studies are required to elucidate the role of inflammation on the risk of VTE. This study was supported by FAPESP (2005/56799-0). Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4648-4648
Author(s):  
Nora Butta ◽  
María Isabel Rivas Pollmar ◽  
María Teresa Álvarez Román ◽  
Monica Martín Salces ◽  
Ihosvany Fernandez Bello ◽  
...  

Abstract Background: Patients with ITP have a wide variation in the presentation of the disease, platelet count and their clinical course. The decision to begin treatment is based on the hemorrhagic symptoms and platelet count. Intravenous immunoglobulin (IVIG) is usually associated with glucocorticoid administration in patients with severe bleeding or platelet counts <20x109/L and a quick response is required. Agonists of thrombopoietin receptor (TPO-AR) and splenectomy are other therapeutic tools for these patients. Materials and Methods: We recruited patients with ITP before and after responding to treatment with IVIG (n = 11) and AR-TPO (4 patients with romiplostim and 10 with eltrombopag), 5 splenectomized patients and 82 healthy controls. The percentage of reticulated platelets, platelet activation and binding of annexin-V were evaluated by flow cytometry. Plasma levels of TPO and "a proliferation-inducing ligand" (APRIL) were determined by ELISA. Procoagulant activity associated microparticles (MP) and the ability of plasma to generate thrombin were determined, respectively, with Zymuphen kit and calibrated automated thrombinography (CAT) triggered by 1 pM tissue factor and 4 micromolar phospholipid (PPP-low reagent, Diagnostica Stago, Spain). Results: Patients with ITP that respond to IGIV and AR-TPO treatments recovered platelet counts without reaching the levels of the control group, whereas the platelet count in splenectomized patients did not differ from it. Plasma levels of TPO and the number of immature platelets in the first two groups were higher than in controls before responding to treatment. Despite recovering platelet count, platelet capacity of being activated by agonists such as TRAP (thrombin receptor agonist for PAR-1) was less than that of the controls in all groups. This decrease was not due to a reduction in the expression of the fibrinogen receptor on platelets from ITP patients. Platelets from ITP patients before and after responding to all treatments studied, showed more phosphatidylserine exposure and greater microparticles-associated and plasma-associated procoagulant activity. Plasma levels of APRIL, a factor that stimulates B cells and antibody production, decreased in ITP patients who responded to the AR-TPO, reaching the levels observed in the control group. In the group of splenectomized patients a decrease of APRIL was also observed, but still remained higher than in healthy controls. Conclusions: ITP patients who respond to treatment with IVIG and AR-TPO and undergoing splenectomy recovered platelet count but not its function. The treatments did not modify the microparticles- and plasma-associated thrombogenic capacity. Among all the treatments studied, AR-TPO and splenectomy had an addittional benefical effect reducing APRIL plasma levels Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2561-2561
Author(s):  
Xiaomei Ge ◽  
Yasuto Yamaguchi ◽  
Lei Zhao ◽  
Loredana Bury ◽  
Paolo Gresele ◽  
...  

Abstract Chemerin is a chemoattractant and adipokine that circulates in blood as inactive prochemerin (chem163S). Chem163S is activated by a series of C-terminal proteolytic cleavages resulting in diverse chemerin forms with different levels of activity. Cleavage of chem163S at Lys158 generates chem158K, which has low bioactivity, with subsequent cleavage by the basic carboxypeptidases in plasma, carboxypeptidase N (CPN) or thrombin-activatable CPB2 (also known as thrombin-activatable fibrinolysis inhibitor or TAFI), to produce chem157S, the most active form of chemerin. Inactivation of chem157S to chem155A and smaller forms of chemerin occurs by further proteolytic cleavages. We have developed specific ELISAs for chem163S, 158K, 157S and 155A. Using these chemerin-specific ELISAs, we found that most of the chemerin in normal human plasma is inactive chem163S, while chem158K is the dominant form in synovial fluids of arthritis patients. To identify the physiological activator of chemerin in plasma, we screened proteases from the coagulation, fibrinolytic and complement pathways. The proteases were incubated with purified chem163S protein in buffer and the resultant products were analyzed by MALDI-TOF mass spectrometry. The results showed that Factor XIa (FXIa) can cleave chem163S, generating a novel chemerin form, chem162R, as an intermediate product, and chem158K, as the final product. We compared the kinetics of FXIa cleavage of chem163S and FIX, the established physiological FXIa substrate. Peptides from chem163S and FIX containing the FXIa cleavage site were subjected to FXIa cleavage followed by HPLC analysis. The catalytic efficiency (kcat/KM) of FXIa cleavage of FIX was ~3-fold more efficient than chemerin cleavage, but the hydrolysis of chem163S still occurred at a physiologically relevant rate. By substituting Arg162 with Ala in chemerin protein/peptides, we found that processing at Arg162 was not required for cleavage at Lys158 or regulation of chemerin bioactivity. We further investigated FXIa cleavage of chem163 in plasma triggered by kaolin to activate FXI. FXI activity was measured by inclusion of a specific chromogenic substrate, and chemerin levels were measured by the chemerin-specific ELISAs. Contact phase activation of human platelet-poor plasma led to generation of FXIa and cleavage of chem163S, which was abolished in FXI-depleted plasma. Platelets markedly enhanced FXI activation and chem163S cleavage in platelet-rich plasma comparing to platelet-poor plasma. Following contact activation, plasma levels of the most potent form of chemerin, chem157S, as well as inactive chem155A, increased. Plasma levels of chem163S in FXI-deficient patients were significantly higher compared to a matched control group (90.69±9.6 ng/mL vs. 58.11±2.51 ng/mL, n=8; P<0.01) and inversely correlated with the plasma FXI levels. FXIa, generated upon contact phase activation, cleaves chem163S to generate chem158K, which can be further processed to the most active chemerin form, thus providing a molecular link between coagulation, inflammation, innate immunity and adipogenesis. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document